AstraZeneca-Daiichi's Enhertu reports positive survival rate results
Daiichi Sankyo Co. Ltd.
n/a
10:20 20/12/24
A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.
AstraZeneca
10,460.00p
17:00 27/12/24
FTSE 100
8,149.78
16:54 27/12/24
FTSE 350
4,495.62
16:29 27/12/24
FTSE All-Share
4,453.14
17:05 27/12/24
Pharmaceuticals & Biotechnology
20,065.81
16:29 27/12/24
The drug, Enhertu, is an antibody treatment that targets cancers linked to a protein known as HER2.
A clinical trial of more than 550 patients found those using the drug had a 49% reduction in risk of the cancer progressing and a 36% reduction in risk of death compared to those on chemotherapy treatment.
"The results show for the first time that a HER2-directed therapy can provide a survival benefit to patients with low HER2 expression, indicating we must reconsider the way we categorise patients with metastatic breast cancer,” said Shanu Modi, a medical oncologist and principal investigator for the trial.